HUTCHMED Announces China NDA Acceptance And Priority Review For Fanregratinib Supported By Phase II Registration Trial Results
Benzinga Newsdesk 10 months ago
News
NDA supported by results from a Phase II registration trial in China —— Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in compariso
- NDA supported by results from a Phase II registration trial in China —
- — Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in compariso